No records
|
671 |
Irawan C., Rachman A., Rahman P., Mansjoer A. |
28767651600;15056701600;57336745700;24335647800; |
Role of Pretreatment Hemoglobin-to-Platelet Ratio in Predicting Survival Outcome of Locally Advanced Nasopharyngeal Carcinoma Patients |
2021 |
Journal of Cancer Epidemiology |
2021 |
|
1103631 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118993816&doi=10.1155%2f2021%2f1103631&partnerID=40&md5=82e487803fe00d9c97bbac4301d585e1 |
Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Clinical Epidemiology Unit, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Irawan, C., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rachman, A., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rahman, P., Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Mansjoer, A., Clinical Epidemiology Unit, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Background. The three-year survival rate of locally advanced nasopharyngeal carcinoma (NPC) patients in Indonesia is lower than in other Asian countries. Calculation of hemoglobin-to-platelet ratio (HPR) may become a more practical predictor than the ratios using leukocyte cell components. Yet, no study has been conducted to investigate the potential of HPR in predicting survival outcomes in locally advanced nasopharyngeal cancer patients. Objective. To determine the role of pretreatment hemoglobin-to-platelet ratio in predicting the three-year overall survival (OS) of locally advanced NPC. Method. A retrospective cohort study followed up on 289 locally advanced NPC patients who had undergone therapy at the Dr. Cipto Mangunkusumo National General Hospital between January 2012 and October 2016. HPR cut-off was determined using ROC. Subjects were classified into two groups according to the HPR value. Kaplan-Meier curve was utilized to illustrate patients' three-year survival, and Cox regression test analyzed confounding variables to yield an adjusted hazard ratio (HR). Results. The optimal cut-off for HPR was 0.362 (AUC 0.6228, 95% CI: 0.56-0.69, sensitivity 61.27%, specificity 60.34%). Of the subjects, 48.44% had HPR≤0.362, and they had a higher three-year mortality rate than those with HPR>0.362 (50% vs. 31.54%). In bivariate analysis, HPR≤0.362 and age≥60 significantly showed a worse three-year OS (p value = 0.003 and 0.075, respectively). In multivariate analysis, we concluded that a pretreatment HPR≤0.362 was an independent negative predictor of three-year OS in locally advanced NPC patients (adjusted HR 1.82; 95% CI: 1.25-2.65). Conclusion. Pretreatment HPR≤0.362 was a negative predictor of three-year OS in locally advanced nasopharyngeal cancer patients. © 2021 Cosphiadi Irawan et al. |
|
antineoplastic agent; hemoglobin; adjuvant therapy; adult; advanced cancer; area under the curve; Article; cancer chemotherapy; cancer mortality; cancer patient; cancer prognosis; cancer radiotherapy; cancer survival; clinical outcome; cohort analysis; conformal radiotherapy; controlled study; female; follow up; general hospital; hematological parameters; hemoglobin blood level; hemoglobin to platelet ratio; human; human cell; intensity modulated radiation therapy; locally advanced nasopharyngeal carcinoma; major clinical study; male; middle aged; multiple cycle treatment; nasopharynx carcinoma; neoadjuvant chemotherapy; nutritional status; overall survival; platelet count; receiver operating characteristic; reference value; retrospective study; sensitivity and specificity; survival predic |
Hindawi Limited |
16878558 |
|
|
Article |
Q2 |
783 |
6201 |
|
|
672 |
Tunjungputri R.N., Tetrasiwi E.N., Veronica M., Pandelaki J., Ibrahim F., Nelwan E.J. |
56342194400;57267704700;57268337000;35759266900;54886001500;14527452900; |
Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19 |
2021 |
Case Reports in Medicine |
2021 |
|
9673453 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118971098&doi=10.1155%2f2021%2f9673453&partnerID=40&md5=ddb9dd4ce5b8de10f0e4c9c43c6cd496 |
Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Radiology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Microbiology Department, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Infectious Disease and Immunology Research Center - IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Tunjungputri, R.N., Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Tetrasiwi, E.N., Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Veronica, M., Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Pandelaki, J., Department of Radiology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Ibrahim, F., Microbiology Department, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Nelwan, E.J., Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia, Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia, Infectious Disease and Immunology Research Center - IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Introduction. The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-associated disease enhancement (VADE) is the modified presentation of infections in individuals after having received a prior vaccination. Currently, little is known about the potential of vaccine-associated disease enhancement (VADE) following COVID-19 immunization. Case Illustration. We herewith report two patients admitted with confirmed COVID-19 pneumonia with a history of CoronaVac vaccination. The first patient with a relatively milder course of the disease had received two doses of CoronaVac, whereas the second patient with a more progressive course of the disease received only one dose before developing symptoms and being admitted to the hospital. Our observations suggest that vaccination could act in boosting the inflammatory process and reveal the previously asymptomatic COVID-19 illness. Theoretically, vaccines could induce VADE, where only suboptimal, nonprotective titers of neutralizing antibodies were produced or proinflammatory T-helper type 2 response was induced. Secondly, enhanced respiratory disease (ERD) could manifest, where pulmonary symptoms are more severe due to peribronchial monocytic and eosinophilic infiltration. Understanding VADE is important for the decision-making by the public, clinicians, and policymakers and is warranted for successful vaccination uptake. Conclusion. We report two cases of patients developing COVID-19 shortly after CoronaVac vaccination in which VADE is likely. We recommend that current vaccination strategies consider the measurement of neutralizing antibody titer as a guide in ensuring the safest strategy for mass immunization. Studies are needed to investigate the true incidence of VADE on vaccinated individuals as well as on how to differentiate between VADE and severe manifestations of COVID-19 that are unrelated to vaccination. © 2021 Rahajeng N. Tunjungputri et al. |
|
C reactive protein; coronavac; D dimer; fibrinogen; hemoglobin; neutralizing antibody; procalcitonin; adult; antibody titer; Article; asymptomatic coronavirus disease 2019; blood pressure; calcitonin blood level; case report; clinical article; coronavirus disease 2019; COVID-19 testing; electrocardiography; fibrinogen blood level; heart right bundle branch block; hemoglobin blood level; hospital admission; human; hyperglycemia; hypokalemia; hyponatremia; hypoosmolarity; inflammation; laboratory test; leukocyte count; lung examination; male; medical history; middle aged; physical examination; platelet count; protein blood level; real time polymerase chain reaction; thorax radiography; vaccination; vaccine associated disease enhancement; vaccine associated disease enhancement; young adult |
Hindawi Limited |
16879627 |
|
|
Article |
Q4 |
200 |
19317 |
|
|
673 |
Kaaffah S., Soewondo P., Riyadina W., Renaldi F.S., Sauriasari R. |
57331465300;23475336100;57208470391;57331465400;16246507200; |
Adherence to treatment and glycemic control in patients with type 2 diabetes mellitus: A 4-year follow-up ptm bogor cohort study, indonesia |
2021 |
Patient Preference and Adherence |
15 |
|
|
2467 |
2477 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118951660&doi=10.2147%2fPPA.S318790&partnerID=40&md5=079f3b92c2c91638e7785757da719eff |
Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; Division of Endocrinology, Department of Internal Medicine, Dr.Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Metabolic, Cardiovascular and Aging Cluster, The Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; National Institute of Health Research and Development, Ministry of Health Republic of Indonesia, Jakarta, Indonesia |
Kaaffah, S., Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; Soewondo, P., Division of Endocrinology, Department of Internal Medicine, Dr.Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Metabolic, Cardiovascular and Aging Cluster, The Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Riyadina, W., National Institute of Health Research and Development, Ministry of Health Republic of Indonesia, Jakarta, Indonesia; Renaldi, F.S., Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; Sauriasari, R., Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia |
Purpose: Large-scale evaluation of the treatment adherence in patients with type 2 diabetes mellitus (DM) in Indonesian is limited. We aim to evaluate the treatment adherence of Indonesian type 2 DM patients using national “big data” and investigate its association with glycemic parameters. Patients and Methods: We analyzed baseline and fourth-year data sets from 2011 to 2018 obtained from the Indonesian Ministry of Health Cohort Study of Non-Communicable Disease Risk Factors in Bogor, West Java (the PTM Bogor Cohort Study). This was a retrospective cohort study in which the sample was divided into two groups. One group adhered to treatment from primary health centers and followed the prescribed medicine/ treatment regimen (treated group), while the other did not follow the treatment (untreated group). We evaluated changes in fasting blood glucose (FBG) and post-prandial blood glucose (PPBG) by controlling for other variables. Results: From 5690 subjects, 593 were type 2 DM diagnosed and 342 were eligible at the baseline. At 4-year observation, 212 eligible patients remained, consisting of 62 subjects who adhered to treatment, and more than double that number who were untreated (150 subjects). More significant decreases in FBG and PPBG were found in the treated group (FBG 80.6%, PPBG 90.3%) than in the untreated group (FBG 42.0%, PPBG 67.3%). The results of the multivariate analysis showed that after 4 years observation, treated patients have reduced FBG 3.304 times more and PPBG 3.064 times more than untreated patients, with control factors such as decrease in LDL levels and use of oral drugs. Conclusion: There were less than half as many treated patients as untreated patients involved in the PTM Bogor Study Group. At the fourth-year follow-up, treated patients experienced three times more significant decreases in FBG and PPBG than those who were untreated, even after being controlled by several confounding factors. Given the importance of these findings, it is suggested that immediate strategic action be taken to improve Indonesian patients’ adherence to treatment. © 2021 Kaaffah et al. |
Cohort; Diabetes mellitus; Fasting blood glucose; Post-prandial blood glucose; Treatment adherence |
glibenclamide; glimepiride; glucose; insulin; low density lipoprotein; metformin; sulfonylurea; adult; Article; big data; cohort analysis; controlled study; fasting; female; follow up; glucose blood level; glycemic control; human; Indonesia; major clinical study; male; medication compliance; middle aged; non insulin dependent diabetes mellitus; patient compliance; prescription; primary health care; retrospective study |
Dove Medical Press Ltd |
1177889X |
|
|
Article |
Q1 |
885 |
5263 |
|
|
674 |
Sobri F.B., Bachtiar A., Panigoro S.S., Ayuningtyas D., Gustada H., Yuswar P.W., Nur A.A., Putri R.C.R.A., Widihidayati A.D. |
57217500979;56683183900;56790104300;56461361200;57195940157;57253490900;57328088400;57328181200;57328088500; |
Factors Affecting Delayed Presentation and Diagnosis of Breast Cancer in Asian Developing Countries Women: A Systematic Review |
2021 |
Asian Pacific Journal of Cancer Prevention |
22 |
10 |
|
3081 |
3092 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118798481&doi=10.31557%2fAPJCP.2021.22.10.3081&partnerID=40&md5=6febc7b64c7dfeddec8aeff299b230ac |
Faculty of Public Health, Universitas Indonesia, Depok, Indonesia; Department of Health Policy and Administration, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia; Department of Surgery, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Pondok Indah Hospital, Jakarta, Indonesia; Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia |
Sobri, F.B., Faculty of Public Health, Universitas Indonesia, Depok, Indonesia; Bachtiar, A., Department of Health Policy and Administration, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia; Panigoro, S.S., Department of Surgery, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Ayuningtyas, D., Department of Health Policy and Administration, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia; Gustada, H., Pondok Indah Hospital, Jakarta, Indonesia; Yuswar, P.W., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Nur, A.A., Faculty of Public Health, Universitas Indonesia, Depok, Indonesia; Putri, R.C.R.A., Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Widihidayati, A.D., Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia |
Background: Advance in screening strategies and management had steadily decreased the mortality rates of breast cancer. In developing countries, conducting screening and early diagnosis of breast cancers may face several problems. This systematic review aims to determine factors affecting the delayed diagnosis of breast cancer in developing countries in Asia. Methods: Literature research was conducted through Pubmed, ScienceDirect, Scopus, EbscoHost, Cochrane Library, and Google Scholar. The main keywords were “breast cancer”, “delayed diagnosis” and “developing countries”. Both quantitative and qualitative studies were included. Results: A total of 26 studies were included. The definition of delayed presentation or diagnosis varied from 1 month to 6 months. Among all the factors from patients and providers, breast symptoms and examinations consistently showed a significant contribution in reducing delayed diagnosis. Strengthened by qualitative studies, patients’ knowledge and perception also had a major role in delayed diagnosis. Conclusion: Among Asian developing countries, breast symptoms and examination, as well as individual knowledge and perception, are the main factors related to delayed diagnosis of breast cancer. © 2021. All Rights Reserved. |
Asian developing countries; breast cancer; delayed diagnosis; delayed presentation; examination; knowledge |
Asia; Asian; attitude to health; breast tumor; delayed diagnosis; developing country; female; human; symptom assessment; time factor; Asia; Asians; Breast Neoplasms; Delayed Diagnosis; Developing Countries; Female; Health Knowledge, Attitudes, Practice; Humans; Symptom Assessment; Time Factors |
Asian Pacific Organization for Cancer Prevention |
15137368 |
|
34710982 |
Article |
Q2 |
512 |
9866 |
|
|
675 |
Anton J., Sudibio S., Handoko H., Permata T.B.M., Kodrat H., Nuryadi E., Sofyan H., Susanto E., Mulyadi R., Aman R.A., Gondhowiardjo S. |
57328462500;57283461500;57204105168;57197808751;57210639849;57197806814;57328366500;57204423225;56403164500;36848942500;6508327402; |
Overexpression of c-Met is Associated with Poor Prognosis in Glioblastoma Multiforme: A Systematic Review and Meta-Analyses |
2021 |
Asian Pacific Journal of Cancer Prevention |
22 |
10 |
|
3075 |
3080 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118768203&doi=10.31557%2fAPJCP.2021.22.10.3075&partnerID=40&md5=1f49d5bfee87f5293659fdc801e6d63a |
Department of Radiation Oncology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Neurology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Pathology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Radiology, dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia |
Anton, J., Department of Radiation Oncology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sudibio, S., Department of Radiation Oncology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Handoko, H., Department of Radiation Oncology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Permata, T.B.M., Department of Radiation Oncology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Kodrat, H., Department of Radiation Oncology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Nuryadi, E., Department of Radiation Oncology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sofyan, H., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Neurology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Susanto, E., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Pathology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Mulyadi, R., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Radiology, dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Aman, R.A., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Neurology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Gondhowiardjo, S., Department of Radiation Oncology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Objective: The aim of this study is to evaluate the association of c-Met overexpression with survival of glioblastoma multiforme (GBM) patients. Methods: A systematic review with meta-analyses was conducted on related articles from PubMed, EBSCOhost, Scopus, and Cochrane databases with last updated search on October 31, 2020. A total of 7 studies regarding c-Met overexpression and overall survival (OS) and/or progression free survival (PFS) are included in this study. Results: All studies used immunohistochemistry to examine the expression of c-Met protein. The results showed that the positive rate of c-Met overexpression was detected in approximately 33,9% - 60,5% of GBM patients. c-Met overexpression was related to worse OS (HR: 1,74; 95% CI: 1,482-2,043; Z=6,756; p<0,001) and PFS (HR: 1,66; 95% CI: 1,327-2,066; Z=4,464; p<0,001) in GBM patients. Low heterogeneity of subjects was found in both OS and PFS analyses, I2 values were 7,8% and 0,0%, respectively. Conclusion: In conclusion, c-Met overexpression is significantly related to shorter OS and PFS in GBM patients, so c-Met can be considered as a potential prognostic indicator in GBM. © 2021. All Rights Reserved. |
c-Met; glioblastoma multiforme; prognosis; survival |
MET protein, human; scatter factor receptor; brain tumor; glioblastoma; human; Kaplan Meier method; meta analysis; metabolism; mortality; prognosis; Brain Neoplasms; Glioblastoma; Humans; Kaplan-Meier Estimate; Prognosis; Progression-Free Survival; Proto-Oncogene Proteins c-met |
Asian Pacific Organization for Cancer Prevention |
15137368 |
|
34710981 |
Article |
Q2 |
512 |
9866 |
|
|
676 |
Agarwal A., Sharma R.K., Gupta S., Boitrelle F., Finelli R., Parekh N., Durairajanayagam D., Saleh R., Arafa M., Cho C.L., Farkouh A., Rambhatla A., Henkel R., Vogiatzi P., Tadros N., Kavoussi P., Ko E., Leisegang K., Kandil H., Palani A., Salvio G., Mostafa T., Rajmil O., Banihani S.A., Schon S., Le T.V., Birowo P., Çeker G., Alvarez J., Molina J.M.C., Ho C.C.K., Calogero A.E., Khalafalla K., Duran M.B., Kuroda S., Colpi G.M., Zini A., Anagnostopoulou C., Pescatori E., Chung E., Caroppo E., Dimitriadis F., Pinggera G.-M., Busetto G.M., Balercia G., Elbardisi H., Taniguchi H., Park H.J., Rosas I.M., de la Rosette J., Ramsay J., Bowa K., Simopoulou M., Rodriguez M.G., Sabbaghian M., Martinez M., Gilani M.A.S., Al-Marhoon M.S., Kosgi R., Cannarella R., Micic S., Fukuhara S., Parekattil S., Jindal S., Abdel-Meguid T.A.-A., Morimoto Y., Shah R. |
7401480880;56464514400;8924915200;35306701900;57210196522;57196694810;55520166400;7006807491;23098964500;57197761284;57208753862;23398404000;16194084100;55926424800;6701691160;13805293700;54894624400;55522599700;57225096159;57195328571;57191592841;14060837800;6602414666;55393128900;36119073400;57327390400;6504153311;57445145100;7402573357;57214102315;57327957600;7006656219;57188552644;57216609982;57327256700;7004721256;7005212511;57225111834;7003338300;57327111700;6602342322;15126468500;6603547664;37049750600;56259951900;56711976600;22836833700;57327528100;57225111015;7102844406;7103327153;24721453900;6506988003;57225094450;24451370900;57214939051;57327818500;9247352000;57195955297;56033761100;7006493137;8635237400;6506341654;57214937086;6508134167;36051984500;23470471000; |
Sperm vitality and necrozoospermia: diagnosis, management, and results of a global survey of clinical practice |
2021 |
World Journal of Men's Health |
39 |
|
210149 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118736952&doi=10.5534%2fwjmh.210149&partnerID=40&md5=776ce144f9bcad4451df84b64415ccd7 |
American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Reproductive Biology, Fertility Preservation, Andrology, CECOS, Poissy Hospital, Poissy, France; Paris Saclay University, UVSQ, INRAE, BREED, Jouy-en-Josas, France; Department of Urology, Cleveland Clinic, Cleveland, OH, United States; Department of Physiology, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Selangor, Malaysia; Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt; Department of Urology, Hamad Medical Corporation, Doha, Qatar; Department of Urology, Weill Cornell Medical-Qatar, Doha, Qatar; SH Ho Urology Center, Department of Surgery, Chinese University of Hong Kong, Hong Kong; Department of Urology, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, United States; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom; Department of Medical Bioscience, University of the Western Cape, Bellville, South Africa; LogixX Pharma, Berkshire, Theale, United Kingdom; Andromed Health and Reproduction, Fertility Diagnostics Laboratory, Maroussi, Greece; Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, United States; Austin Fertility and Reproductive Medicine/Westlake IVF, Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States; Department of Urology, Loma Linda University Health, Loma Linda, CA, United States; Department of Physiology, School of Natural Medicine, Faculty of Community and Health Sciences, University of the Western Cape, Bellville, South Africa; Fakih IVF Fertility Center, Abu Dhabi, United Arab Emirates; Department of Biochemistry, College of Medicine, University of Garmian, Kalar, Iraq; Department of Endocrinology and Metabolic Diseases, Polytechnic University of Marche, Ancona, Italy; Department of Andrology, Sexology and STIs, Faculty of Medicina, Cairo University, Cairo, Egypt; Department of Andrology, Fundacio Puigvert, Barcelona, Spain; Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, United States; Department of Andrology and Urology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam; Department of Andrology, Binh Dan Hospital, Ho Chi Minh City, Viet Nam; Department of Urology, Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Urology, Samsun Vezirköprü State Hospital, Samsun, Turkey; Centro ANDROGEN, La Coruña, Spain; Servicio de Urología, Hospital Clínico de Barcelona, Barcelona, Spain; Department of Surgery, School of Medicine, Faculty of Health and Medical Sciences, Taylor’s University, Subang Jaya, Malaysia; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; Department of Urology, Samsun Training and Research Hospital, Samsun, Turkey; Andrology and IVF Unit, Procrea Institute, Lugano, Switzerland; Department of Surgery, McGill University, Montreal, QC, Canada; IVF Clinic “Akeso-Embryo ART”, Athens, Greece; Andrology and Reproductive Medicine Unit, Gynepro Medical, Bologna, Italy; Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia; AndroUrology Centre, Brisbane, QLD, Australia; Reproductive and IVF Unit, Andrology Outpatients Clinic, ASL Bari, Conversano (Ba), Italy; 1st Urology Department, School of Medicine, Aristotle University, Thessaloniki, Greece; Department of Urology, Innsbruck Medical University, Innsbruck, Austria; Department of Urology and Renal Transplantation, University of Foggia, Ospedali Riuniti of Foggia, Foggia, Italy; Department of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan; Department of Urology, Pusan National University School of Medicine, Busan, South Korea; Medical Research Institute, Pusan National University Hospital, Busan, South Korea; Citmer Reproductive Medicine, IVF LAB, Mexico City, Mexico; Department of Urology, Medipol Mega University Hospital, Istanbul, Turkey; Department of Andrology, Hammersmith Hospital, London, United Kingdom; Department of Urology, Michael Chilufya Sata Copperbelt University School of Medicine, Ndola, Zambia; Department of Experimental Physiology, School of Health Sciences, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Departamento Docencia e Investigación, Hospital Militar Campo de Mayo, Universidad Barcelo, Buenos Aires, Argentina; Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran; Section of Urology, University of Santo Tomas Hospital, Manila, Philippines; Department of Surgery, Urology Division, Sultan Qaboos University, Muscat, Oman; Department of Urology and Andrology, AIG Hospitals, Gachibowli, Hyderabad, India; Department of Andrology, Uromedica Polyclinic, Belgrade, Serbia; Department of Urology, Graduate School of Medicine, Osaka University, Osaka, Japan; Avant Concierge Urology, University of Central Florida, Winter Garden, FL, United States; Department of Andrology and Reproductive Medicine, Jindal Hospital, Meerut, India; Department of Urology, Faculty of Medicine, Minia University, Minia, Egypt; Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; HORAC Grand Front Osaka Clinic, Osaka, Japan; Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India |
Agarwal, A., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Sharma, R.K., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Gupta, S., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Boitrelle, F., Reproductive Biology, Fertility Preservation, Andrology, CECOS, Poissy Hospital, Poissy, France, Paris Saclay University, UVSQ, INRAE, BREED, Jouy-en-Josas, France; Finelli, R., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Parekh, N., Department of Urology, Cleveland Clinic, Cleveland, OH, United States; Durairajanayagam, D., Department of Physiology, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Selangor, Malaysia; Saleh, R., Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, Egypt; Arafa, M., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States, Department of Urology, Hamad Medical Corporation, Doha, Qatar, Department of Urology, Weill Cornell Medical-Qatar, Doha, Qatar; Cho, C.L., SH Ho Urology Center, Department of Surgery, Chinese University of Hong Kong, Hong Kong; Farkouh, A., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Rambhatla, A., Department of Urology, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, United States; Henkel, R., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom, Department of Medical Bioscience, University of the Western Cape, Bellville, South Africa, LogixX Pharma, Berkshire, Theale, United Kingdom; Vogiatzi, P., Andromed Health and Reproduction, Fertility Diagnostics Laboratory, Maroussi, Greece; Tadros, N., Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, United States; Kavoussi, P., Austin Fertility and Reproductive Medicine/Westlake IVF, Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States; Ko, E., Department of Urology, Loma Linda University Health, Loma Linda, CA, United States; Leisegang, K., Department of Physiology, School of Natural Medicine, Faculty of Community and Health Sciences, University of the Western Cape, Bellville, South Africa; Kandil, H., Fakih IVF Fertility Center, Abu Dhabi, United Arab Emirates; Palani, A., Department of Biochemistry, College of Medicine, University of Garmian, Kalar, Iraq; Salvio, G., Department of Endocrinology and Metabolic Diseases, Polytechnic University of Marche, Ancona, Italy; Mostafa, T., Department of Andrology, Sexology and STIs, Faculty of Medicina, Cairo University, Cairo, Egypt; Rajmil, O., Department of Andrology, Fundacio Puigvert, Barcelona, Spain; Banihani, S.A., Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan; Schon, S., Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, United States; Le, T.V., Department of Andrology and Urology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam, Department of Andrology, Binh Dan Hospital, Ho Chi Minh City, Viet Nam; Birowo, P., Department of Urology, Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Çeker, G., Department of Urology, Samsun Vezirköprü State Hospital, Samsun, Turkey; Alvarez, J., Centro ANDROGEN, La Coruña, Spain; Molina, J.M.C., Servicio de Urología, Hospital Clínico de Barcelona, Barcelona, Spain; Ho, C.C.K., Department of Surgery, School of Medicine, Faculty of Health and Medical Sciences, Taylor’s University, Subang Jaya, Malaysia; Calogero, A.E., Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; Khalafalla, K., Department of Urology, Hamad Medical Corporation, Doha, Qatar; Duran, M.B., Department of Urology, Samsun Training and Research Hospital, Samsun, Turkey; Kuroda, S., American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, United States; Colpi, G.M., Andrology and IVF Unit, Procrea Institute, Lugano, Switzerland; Zini, A., Department of Surgery, McGill University, Montreal, QC, Canada; Anagnostopoulou, C., IVF Clinic “Akeso-Embryo ART”, Athens, Greece; Pescatori, E., Andrology and Reproductive Medicine Unit, Gynepro Medical, Bologna, Italy; Chung, E., Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia, AndroUrology Centre, Brisbane, QLD, Australia; Caroppo, E., Reproductive and IVF Unit, Andrology Outpatients Clinic, ASL Bari, Conversano (Ba), Italy; Dimitriadis, F., 1st Urology Department, School of Medicine, Aristotle University, Thessaloniki, Greece; Pinggera, G.-M., Department of Urology, Innsbruck Medical University, Innsbruck, Austria; Busetto, G.M., Department of Urology and Renal Transplantation, University of Foggia, Ospedali Riuniti of Foggia, Foggia, Italy; Balercia, G., Department of Endocrinology and Metabolic Diseases, Polytechnic University of Marche, Ancona, Italy; Elbardisi, H., Department of Urology, Hamad Medical Corporation, Doha, Qatar, Department of Urology, Weill Cornell Medical-Qatar, Doha, Qatar; Taniguchi, H., Department of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan; Park, H.J., Department of Urology, Pusan National University School of Medicine, Busan, South Korea, Medical Research Institute, Pusan National University Hospital, Busan, South Korea; Rosas, I.M., Citmer Reproductive Medicine, IVF LAB, Mexico City, Mexico; de la Rosette, J., Department of Urology, Medipol Mega University Hospital, Istanbul, Turkey; Ramsay, J., Department of Andrology, Hammersmith Hospital, London, United Kingdom; Bowa, K., Department of Urology, Michael Chilufya Sata Copperbelt University School of Medicine, Ndola, Zambia; Simopoulou, M., Department of Experimental Physiology, School of Health Sciences, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Rodriguez, M.G., Departamento Docencia e Investigación, Hospital Militar Campo de Mayo, Universidad Barcelo, Buenos Aires, Argentina; Sabbaghian, M., Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran; Martinez, M., Section of Urology, University of Santo Tomas Hospital, Manila, Philippines; Gilani, M.A.S., Department of Andrology, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran; Al-Marhoon, M.S., Department of Surgery, Urology Division, Sultan Qaboos University, Muscat, Oman; Kosgi, R., Department of Urology and Andrology, AIG Hospitals, Gachibowli, Hyderabad, India; Cannarella, R., Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; Micic, S., Department of Andrology, Uromedica Polyclinic, Belgrade, Serbia; Fukuhara, S., Department of Urology, Graduate School of Medicine, Osaka University, Osaka, Japan; Parekattil, S., Avant Concierge Urology, University of Central Florida, Winter Garden, FL, United States; Jindal, S., Department of Andrology and Reproductive Medicine, Jindal Hospital, Meerut, India; Abdel-Meguid, T.A.-A., Department of Urology, Faculty of Medicine, Minia University, Minia, Egypt, Department of Urology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Morimoto, Y., HORAC Grand Front Osaka Clinic, Osaka, Japan; Shah, R., Division of Andrology, Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India |
Sperm vitality testing is a basic semen examination that has been described in the World Health Organization (WHO) Laboratory Manual for the Examination and Processing of Human Semen from its primary edition, 40 years ago. Several methods can be used to test sperm vitality, such as the eosin-nigrosin (E-N) stain or the hypoosmotic swelling (HOS) test. In the 6th (2021) edition of the WHO Laboratory Manual, sperm vitality assessment is mainly recommended if the total motility is less than 40%. Hence, a motile spermatozoon is considered alive, however, in certain conditions an immotile spermatozoon can also be alive. Therefore, the differentiation between asthenozoospermia (pathological decrease in sperm motility) and necrozoospermia (pathological decrease in sperm vitality) is important in directing further investigation and management of infertile patients. The causes leading to necrozoospermia are diverse and can either be local or general, testicular or extra-testicular. The andrological management of necrozoospermia depends on its etiology. However, there is no standardized treatment available presently and practice varies among clinicians. In this study, we report the results of a global survey to understand current practices regarding the physician order of sperm vitality tests as well as the management practices for necrozoospermia. Laboratory and clinical scenarios are presented to guide the reader in the management of necrozoospermia with the overall objective of establishing a benchmark ranging from the diagnosis of necrozoospermia by sperm vitality testing to its clinical management. Copyright © 2021 Korean Society for Sexual Medicine and Andrology |
Asthenozoospermia; Eosine Yellowish-(YS); Infertility; Nigrosin; Spermatozoa; Vitality |
asthenospermia; clinical practice; diagnostic procedure; ejaculation; eosin nigrosin staining; human; hypoosmotic swelling test; infertility therapy; intracytoplasmic sperm injection; male infertility; necrozoospermia; physician; quality control; Review; semen analysis; semen parameters; sperm viability; spermatozoon density; spermatozoon motility; testicular sperm extraction |
Korean Society for Sexual Medicine and Andrology |
22874208 |
|
|
Review |
#N/A |
#N/A |
#N/A |
|
|
677 |
Vandenplas Y., Brough H.A., Fiocchi A., Miqdady M., Munasir Z., Salvatore S., Thapar N., Venter C., Vieira M.C., Meyer R. |
57223670656;37064383600;7006595735;26664817800;7801694370;55390678300;8337607800;35944268900;8270521000;7404078956; |
Current guidelines and future strategies for the management of cow’s milk allergy |
2021 |
Journal of Asthma and Allergy |
14 |
|
|
1244 |
1256 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118723222&doi=10.2147%2fJAA.S276992&partnerID=40&md5=2b3b3cbc9500f0760551157f099bf4c4 |
Vrije Universiteit Brussel (VUB), UZ Brussel, KidZ Health Castle, Brussels, Belgium; Department Women and Children’s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom; Children’s Allergy Service, Evelina Children’s Hospital, Guy’s and St, Thomas’s NHS Foundation Trust, London, United Kingdom; Translational Research in Pediatric Specialities Area, Division of Allergy, Bambino Gesù Children’s Hospital, IRCCS, Piazza Sant’Onofrio, Rome, Italy; Department of Pediatrics, Sheikh Khalifa Medical City, College of Medicine & Health Sciences, Khalifa University, Khalifa, United Arab Emirates; Department of Child Health, Ciptomangunkusumo Hospital-Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Pediatric Department, Hospital “F. Del Ponte”, University of Insubria, Varese, Italy; Gastroenterology, Hepatology and Liver Transplant, Queensland Children’s Hospital, Brisbane, QLD, Australia; University of Colorado, Children’s Hospital Colorado, Denver, CO, United States; Center for Pediatric Gastroenterology-Hospital Pequeno Príncipe, Curitiba, Brazil; Department of Paediatrics, Imperial College, London, United Kingdom; Department Nutrition and Dietetics, University of Winchester, Winchester, United Kingdom |
Vandenplas, Y., Vrije Universiteit Brussel (VUB), UZ Brussel, KidZ Health Castle, Brussels, Belgium; Brough, H.A., Department Women and Children’s Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom, Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom, Children’s Allergy Service, Evelina Children’s Hospital, Guy’s and St, Thomas’s NHS Foundation Trust, London, United Kingdom; Fiocchi, A., Translational Research in Pediatric Specialities Area, Division of Allergy, Bambino Gesù Children’s Hospital, IRCCS, Piazza Sant’Onofrio, Rome, Italy; Miqdady, M., Department of Pediatrics, Sheikh Khalifa Medical City, College of Medicine & Health Sciences, Khalifa University, Khalifa, United Arab Emirates; Munasir, Z., Department of Child Health, Ciptomangunkusumo Hospital-Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Salvatore, S., Pediatric Department, Hospital “F. Del Ponte”, University of Insubria, Varese, Italy; Thapar, N., Gastroenterology, Hepatology and Liver Transplant, Queensland Children’s Hospital, Brisbane, QLD, Australia; Venter, C., University of Colorado, Children’s Hospital Colorado, Denver, CO, United States; Vieira, M.C., Center for Pediatric Gastroenterology-Hospital Pequeno Príncipe, Curitiba, Brazil; Meyer, R., Department of Paediatrics, Imperial College, London, United Kingdom, Department Nutrition and Dietetics, University of Winchester, Winchester, United Kingdom |
Exclusive breast feeding is recommended in all guidelines as the first choice feeding. Cow milk allergy (CMA) can be diagnosed by a diagnostic elimination diet for 2 to 4 weeks with a hypo-allergenic formula, followed by a challenge test with intact cow milk protein. The most often used hypo-allergenic formula for the diagnostic elimination diet and the therapeutic diet is a CM based extensive hydrolysate. CM-based partial hydrolysates cannot be recommended in the management of CMA because of insufficient efficacy and possible reactions, but about half of the infants with CMA may tolerate a partial hydrolysate. The pros and cons of other dietary options are discussed in this paper. The use of an amino acid-based formula and/or rice based hydrolysate formula during the diagnostic elimination and therapeutic diet is debated. When available, there is sufficient evidence to consider rice hydrolysates as an adequate alternative to CM-based hydrolysates, since some infants will still react to the CM hydrolysate. The pros and cons of dietary options such as soy formula, buckwheat, almond, pea or other plant based dietary products are discussed. Although the majority of the plant-based beverages are nutritionally inadequate, some are nutritionally adapted for toddlers. However, accessibility and content vary by country and, thus far there is insufficient evidence on the efficacy and tolerance of these plant-based drinks (except for soy formula and rice hydrolysates) to provide an opinion on them. Conclusion: A diagnostic elimination diet, followed by a challenge remains the diagnostic standard. The use of an awareness tool may result in a decrease of delayed diagnosis. Breastmilk remains the ideal source of nutrition and when not available a CM extensively hydrolyzed formula, rice hydrolysate or amino acid formula should be recommended. More evidence is needed regarding plant-based drinks. © 2021 Vandenplas et al. |
Amino acid formula; Challenge test; Cow milk allergy; Hydrolysate; Plant-based drink; Rice hydrolysate; Soy formula |
alpha 1 antitrypsin; amino acid based formula; beta defensin; beta lactoglobulin; calcium; calgranulin; casein hydrolysate; cyanocobalamin; folic acid; food allergen; immunoglobulin A; immunoglobulin E; immunoglobulin G4; iodine; partial hydrolysate formula; prebiotic agent; probiotic agent; short chain fatty acid; soybean protein; tumor necrosis factor; unclassified drug; vitamin; allergenicity; almond; asthma; awareness; beverage; Bifidobacteriaceae; breast feeding; buckwheat; buffalo milk; camel milk; child growth; Clinical awareness score; colic; cow milk; Cow’s Milk related Symptom Score; dietary compliance; dietary fiber; donkey milk; double blind procedure; eczema; elimination diet; eosinophilic esophagitis; evidence based practice; facial angioedema; food intake; futurology; health |
Dove Medical Press Ltd |
11786965 |
|
|
Review |
Q1 |
1162 |
3475 |
|
|
678 |
Sulistio S., Habib H., Mulyana R.M., Albar I.A. |
57216916380;57216916669;57216915765;57216915796; |
Emergency intubation practices in a tertiary teaching hospital in Jakarta, Indonesia: A prospective observational study |
2021 |
EMA - Emergency Medicine Australasia |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118592756&doi=10.1111%2f1742-6723.13890&partnerID=40&md5=f148a4a939c1e802197c4a35882c3a66 |
Emergency Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Sulistio, S., Emergency Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Habib, H., Emergency Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Mulyana, R.M., Emergency Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Albar, I.A., Emergency Department, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Objective: Intubation is an important competency for emergency doctors. Emergency patients are often unstable, with undifferentiated conditions. There is little time to prepare these patients prior to intubation and so ED intubation may differ from intubation in intensive care units and operating theatres. The present study aims to describe the characteristics of emergency intubation after an administrative policy change within a tertiary teaching hospital in Jakarta, allowing non-anaesthetists to perform intubation in the ED. Methods: Prospective data were collected regarding patients of all age groups who were intubated at the ED of Cipto Mangunkusumo General Hospital, Jakarta, from February 2018 to January 2019. Patient characteristics, intubation attempts, medications used, complications, and disposition were recorded in a self-reported airway registry based on the Australian and New Zealand Emergency Department Airway Registry (ANZEDAR) form. Results: During the 12-month study period, 231 patients, or 41.5% of ED intubated patients were enrolled in the study, and there were 268 intubation attempts on these enrolled patients. The first-pass success rate was 207 out of 231 patients, or 89.6%, with anaesthetist (88.9%), better than emergency doctors (55.4%). Complications were reported in 51 patients, or 22.0%, with desaturation and hypotension being the most common. Thirty-three patients, or 14.3%, died in the ED before being transferred to another unit. Conclusions: The first-pass success rate is comparable with international data. Non-anaesthetic physicians must improve their experience to achieve a favourable success rate. The data on complications highlight the need for improvement in Indonesian ED intubation practices. © 2021 Australasian College for Emergency Medicine |
airway complications; airway management; emergency medicine; rapid sequence intubation; registry |
|
John Wiley and Sons Inc |
17426731 |
|
|
Article |
Q2 |
602 |
8388 |
|
|
679 |
Akbar R., George Y., Madjid A.S., Sedono R., Tantri A. |
57317624300;26027840300;57163353500;56660590500;57188933853; |
Early administration of norepinephrine prevents the occurrence of fluid overload in the resuscitation of septic shock patients |
2021 |
Critical Care and Shock |
September 2021 |
|
|
257 |
268 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118270800&partnerID=40&md5=d27a72a8961cf30e6da6e5952895aa23 |
Trainee of Intensive Care Fellowship Program, University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Medical Faculty, Haluoleo University-Konawe General Hos-pital, Konawe, Indonesia; Emergency and Intensive Care Unit-Pondok Indah Hospital Jakarta and Departement of Anesthesiology and Intensive Therapy-Faculty of Medicine Universitas, Indonesia; Department of Anesthesiology and Intensive Care, Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia |
Akbar, R., Trainee of Intensive Care Fellowship Program, University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia, Medical Faculty, Haluoleo University-Konawe General Hos-pital, Konawe, Indonesia; George, Y., Emergency and Intensive Care Unit-Pondok Indah Hospital Jakarta and Departement of Anesthesiology and Intensive Therapy-Faculty of Medicine Universitas, Indonesia; Madjid, A.S., Department of Anesthesiology and Intensive Care, Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; Sedono, R., Department of Anesthesiology and Intensive Care, Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia; Tantri, A., Department of Anesthesiology and Intensive Care, Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia |
Background: Critically ill patients with sepsis usually receive a very large volume of fluids cau-sing a very significant positive fluid balance in an effort to meet the needs of cardiac output, syste-mic blood pressure, and perfusion to the kidneys. This condition also tends to be associated with poor survival rates. The aim of this study was to determine whether early maintenance of norepi-nephrine can reduce fluid administration and prevent overload in the resuscitation of patients with septic shock. Methods: This study was a randomized, non-blind clinical trial, of which the subjects were adult patients with septic shock admitted to the intensive and emergency care unit from January to November 2020. There were two treatment groups of this study, the early norepinephrine group (NEP group) and the 30 ml/kgBW fluid resuscitation one (Fluid group). The test was con-ducted on the urinary albumin-to-creatinine ra-tio, increase of serum creatinine value, ratio of arterial oxygen partial pressure to fractional in-spired oxygen (PaO2/FiO2 ratio), and intra-ab-dominal pressure at the time of septic shock di-agnosis was established, 3 hours, and 24 hours . after the treatment was given. The data was pro-cessed using the SPSS device. Results: Based on the analysis, it was found that there were significant differences in all study va-riables of the Fluid group compared to the NEP group. The amount of fluid administration in the NEP group averaged 2198.63 ml, less than that in the Fluid group with an average of 3999.30 ml (chi square test p=0.000). By comparing the measurement results to the initial measurement values in the two groups, the fluid overload was high-risk in the Fluid group. There was a significant relationship between the urinary albumin-to-creatinine ratio (OR=48.273; 95% CI=16.708-139.472), the increase in serum crea-tinine value (OR=73.381; 95% CI=19.955-269.849), the low PaO2/FiO2 ratio (OR=12.225; 95% CI=5.290-28.252), and the increase in intra-abdominal pressure (OR=32.667; 95% CI=10.490-101.724) with the provision of 30 ml/kgBW fluid resuscitation, which indicated the risk of fluid overload. Conclusion: Early norepinephrine administration can reduce fluid administration and prevent overload in the resuscitation of patients with septic shock. © 2021, The Indonesian Foundation of Critical Care Medicine. All rights reserved. |
Early norepinephrine; Fluid overload; Septic shock |
noradrenalin; abdominal pressure; adult; aged; albumin to creatinine ratio; albuminuria; Article; blood volume; capillary leak syndrome; controlled study; creatinine blood level; emergency care; female; fraction of inspired oxygen; Horowitz index; human; hypervolemia; intensive care; major clinical study; male; randomized controlled trial; resuscitation; risk; septic shock; Sequential Organ Failure Assessment Score; systolic blood pressure |
The Indonesian Foundation of Critical Care Medicine |
14107767 |
|
|
Article |
Q4 |
134 |
24890 |
|
|
680 |
Sandora N., Putra M.A., Nurhayati R.W., Suwarti, Nauli R., Kusuma T.R., Fitria N.A., Ardiansyah, Muttaqin C., Makdinata W., Alwi I. |
57204103434;57215605850;55748436600;57212462722;57212478305;57222897694;57148498800;57223036386;57226442135;57223405655;15055173800; |
Characterisation of the single-cell human cardiomyocytes taken from the excess heart tissue of the right ventricular outlet in congenital heart disease |
2021 |
Cell and Tissue Banking |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118214107&doi=10.1007%2fs10561-021-09970-4&partnerID=40&md5=2c4fad90958206777aa1ef5e9ea1e5ec |
Faculty of Medicine, Universitas Riau, Pekanbaru, 28293, Indonesia; Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia |
Sandora, N., Faculty of Medicine, Universitas Riau, Pekanbaru, 28293, Indonesia, Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Putra, M.A., Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Nurhayati, R.W., Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Suwarti, Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Nauli, R., Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Kusuma, T.R., Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Fitria, N.A., Indonesia Medical Education and Research Institute, Jakarta, 10430, Indonesia; Ardiansyah, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Muttaqin, C., Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Makdinata, W., Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Alwi, I., Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia |
Cardiovascular disease is the second highest cause of death across the globe. Myocardial infarction is one of the heart diseases that cause permanent impairment of the heart wall leads to heart failure. Cellular therapy might give hope to regenerate the damaged myocardium. Single cells isolated from an excess heart tissue obtained from the correction of the right ventricular hypertrophy in patients with Tetralogy of Fallot for future heart study were investigated. Methods: Once resected, the heart tissues were transported at 37 °C, in Dulbecco's Modified Eagle's medium/ DMEM (4.5 g.L−1, antibiotic–antimycotic 3x, PRP10% (v/v)), to reach the lab within 30 min, weighted and grouped into less than 500 mg and more than 1000 mg (n = 4). Each sample was digested with 250 U.mL−1 Collagenase type V and 4U.mL−1 Proteinase XXIV in the MACS™ C-tube (Milltenyi, Germany), then dissociated using the MACS™ Octo Dissociator with Heater (Milltenyi, Germany) for 60 min at 37 °C. Results: All cells isolated were rod-shaped cells; viability was up to 90%. The cell density obtained from the 500 mg group were 4,867 ± 899 cells.mg−1 tissue weight, significantly higher compared to the 1,000 mg group; had 557 ± 490 cells.mg−1 tissue weight (mean of (n = 3) ± 95% C.l). The isolated cells were analyzed using FACs BD Flowcytometer, expressed cTnT + 13.38%, PECAM-1 + /VCAM-1- 32.25%, cKit + 7.85%, ICAM + 85.53%, indicating the cardiomyocyte progenitor cells. Conclusion: Cardiomyocytes taken from the wasted heart tissue might be a candidate of cardiomyocytes source to study interventions to the heart as it contained up to 13.38% cardiomyocytes, and 32.25% of cardiac progenitor cells. Moreover, perhaps when cardiac cell therapy needs autologous cardiomyocytes, less than 500 mg tissue weight can be considered as sufficient. © 2021, The Author(s), under exclusive licence to Springer Nature B.V. |
Cardiac progenitor cells; Cardiomyocyte isolation; Right ventricular resection; Tetralogy of fallot; Waste heart tissue |
|
Springer Science and Business Media B.V. |
13899333 |
|
|
Article |
Q3 |
397 |
12196 |
|
|